News ArticleCORONA Remedies Limited Receives ₹4.88 Crore Demand Notice from NPPA Alleging Pricing Violation
The company is reviewing the demand notice issued on November 3, 2026, relating to prior price approval under DPCO 2013 with no material financial impact expected
CORONA Remedies Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) totaling ₹4,87,97,160, including interest and penalty, alleging a violation of the Drugs (Prices Control) Order, 2013. The company is evaluating the notice and states there is no material financial impact from the demand.
CORONA Remedies Limited
Legal / Regulatory
CORONA Remedies Limited announced that it received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) dated November 3, 2026, alleging a violation of the Drugs (Prices Control) Order, 2013, with a total demand amounting to ₹4,87,97,160 including interest and penalty.
The NPPA notice concerns an alleged issue regarding prior price approval under Para 15 of the Drugs (Prices Control) Order, 2013 (DPCO 2013).
CORONA Remedies Limited is currently evaluating the demand notice and intends to take appropriate action in accordance with applicable laws.
The company stated that the demand notice does not have any material financial impact on its operations or finances at this time.
Highlights
- Demand notice issued by NPPA includes ₹4,87,97,160 covering principal amount, interest, and penalty.
- Allegation relates to violation of price approval rules under DPCO 2013.
- Notice was received by the company on November 3, 2026.
- CORONA Remedies Limited is reviewing the demand and will respond legally as appropriate.
- Company confirms no significant financial impact from the notice currently.
Key Data Snapshot
What happened
- CORONA Remedies Limited received a demand notice from NPPA alleging pricing violation under DPCO 2013.
- The demand includes interest and penalty totaling ₹4,87,97,160.
- The company is currently evaluating the demand notice and preparing a response.
Regulatory and governance context
- The demand notice is issued under Para 15 of DPCO 2013, related to prior price approval obligations.
- NPPA is the authority responsible for regulating pharmaceutical prices in India under the Ministry of Chemicals & Fertilizers.
- CORONA Remedies Limited disclosed the demand notice under SEBI LODR Regulations, 2015.
Business impact
- The company confirms the demand notice does not have any material financial impact at present.
- Operational and financial activities remain unaffected as per current assessment.
Highlights
- Demand notice issued by NPPA includes ₹4,87,97,160 covering principal amount, interest, and penalty.
- Allegation relates to violation of price approval rules under DPCO 2013.
- Notice was received by the company on November 3, 2026.
- CORONA Remedies Limited is reviewing the demand and will respond legally as appropriate.
- Company confirms no significant financial impact from the notice currently.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Drugs (Prices Control) Order, 2013
More News on Legal / Regulatory
View allLatest corporate announcements and market updates in Legal / Regulatory.
Dhoot Transmission Limited Confirms Full Utilization of Rs. 1400 Crore IPO Proceeds in Q2 FY27 as Per Monitoring Agency Report
Dhoot Transmission Limited has submitted the Monitoring Agency Report from CARE Ratings Limited for the quarter ended September 30, 2026, confirming that the Rs. 1400 crore fresh issue proceeds raised through its IPO have been fully and appropriately utilized according to the offer document.
Read Full Story
Fractal Analytics Utilizes Rs. 82.1 Crore of IPO Fresh Issue Proceeds in Q2 FY27, CARE Ratings Confirms
Fractal Analytics Limited has utilized Rs. 82.1 crore from its Rs. 1,023.5 crore IPO fresh issue proceeds during the quarter ended September 30, 2026, primarily for product development, marketing, and employee equipment, with no deviations reported by CARE Ratings, the appointed Monitoring Agency.
Read Full Story
Max Healthcare Institute Limited Reports Ongoing Legal Proceedings at NCLT with Next Hearing on December 14, 2026
Max Healthcare Institute Limited has disclosed ongoing litigation at the National Company Law Tribunal (NCLT) Cuttack Bench involving its subsidiary Kalinga Hospital Ltd and other shareholders, with the next NCLT hearing scheduled for December 14, 2026.
Read Full Story
